Valuation: Intervacc AB

Market Cap 397M 41.23M 36.03M 33.25M 30.65M 57.76M 3.97B 59.04M 156M 1.94B 155M 151M 6.69B P/E 2026 *
-5.3x
P/E 2027 * -5.3x
Enterprise Value 304M 31.58M 27.6M 25.47M 23.47M 44.24M 3.04B 45.23M 120M 1.49B 119M 116M 5.13B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 11.1x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-3.80%
1 week-10.86%
Current month-10.58%
1 month-10.31%
3 months-2.02%
6 months+27.29%
Current year+26.19%
1 week 1.14
Extreme 1.14
1.31
1 month 1.14
Extreme 1.14
1.36
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
84
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap.
2/23/25 Free

Chief Financial Officer

929,208 1.2269%
2/17/25 Sell

Chief Executive Officer

278,820 0.3681%
2/17/25 Buy

Chief Executive Officer

135,000 0.1783%
Change 5-day change 1-year change 3-year change Capi.($)
-3.80%-10.86%+17.54%-75.73% 41.23M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.88%-3.45%+38.24%+158.07% 23.36B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.09%

Financials

2026 *2027 *
Net sales 17.7M 1.84M 1.6M 1.48M 1.36M 2.57M 177M 2.63M 6.96M 86.61M 6.9M 6.75M 298M 30.05M 3.12M 2.72M 2.51M 2.32M 4.37M 300M 4.46M 11.82M 147M 11.71M 11.45M 506M
Net income -80.8M -8.38M -7.33M -6.76M -6.23M -11.74M -807M -12.01M -31.78M -395M -31.48M -30.79M -1.36B -83.65M -8.68M -7.58M -7M -6.45M -12.16M -836M -12.43M -32.9M -409M -32.59M -31.88M -1.41B
Net Debt -93M -9.65M -8.43M -7.78M -7.17M -13.52M -929M -13.82M -36.58M -455M -36.24M -35.44M -1.57B -63M -6.54M -5.71M -5.27M -4.86M -9.16M -629M -9.36M -24.78M -308M -24.55M -24.01M -1.06B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-07-17 SEK 1.166 -3.80% 370,510
26-07-16 SEK 1.212 -3.04% 146,658
26-07-15 SEK 1.250 -1.42% 108,813
26-07-14 SEK 1.268 -2.31% 257,239
26-07-13 SEK 1.298 -0.76% 154,826

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock